Related Experiment Video
Updated: Aug 9, 2026
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
European approach to antibody-based immunotherapy of melanoma
Maresa Altomonte1, Michele Maio
1Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.
Abstract:
In the past two decades, the worldwide steadily rising incidence of melanoma, its dismal prognosis when locally advanced or metastatic, and the absence of clinically effective therapeutic options have prompted studies that generated extensive preclinical knowledge on the biology of melanoma cells and their interaction with the host's immune system. As a consequence, among solid tumors, melanoma represents a "model malignancy" to design and apply in the clinic new bioimmunotherapeutic approaches, that are eventually translated to solid tumors of different histotypes. Despite its waxing and waning appeal as a therapeutic strategy, antibody treatment still represents a promising clinical approach to melanoma. Europe is no exception in the clinical interest for antibodies as therapeutic tools in melanoma patients; European researchers have also focused on preclinical issues that may improve current antibody-based therapeutic approaches on the one hand, while providing novel clinical strategies on the other hand.
Insights
Melanoma incidence is rising, prompting research into bioimmunotherapies. Antibody treatments show promise for melanoma patients, with European researchers focusing on improving these approaches.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Rising global incidence of melanoma and poor prognosis for advanced stages necessitate novel therapies.
- Melanoma serves as a model malignancy for developing bioimmunotherapeutic strategies applicable to other solid tumors.
- Antibody treatment, despite fluctuating interest, remains a promising therapeutic avenue for melanoma.
Purpose of the Study:
- To review preclinical knowledge on melanoma biology and immune system interactions.
- To highlight the role of antibody-based therapies in melanoma treatment.
- To discuss European research efforts in advancing antibody therapeutics for melanoma.
Main Methods:
- Review of preclinical studies on melanoma biology and immunology.
- Analysis of clinical data and research trends in antibody-based melanoma treatment.
- Synthesis of European research initiatives in bioimmunotherapy for melanoma.
Main Results:
- Extensive preclinical data exists on melanoma cell biology and host immune interactions.
- Antibody therapies are a key focus for improving melanoma treatment outcomes.
- European research is actively contributing to both preclinical and clinical advancements in melanoma antibody therapy.
Conclusions:
- Melanoma research has generated significant preclinical insights, positioning it as a model for bioimmunotherapy development.
- Antibody treatments offer a promising strategy for managing melanoma, particularly in advanced or metastatic cases.
- Continued European research is crucial for refining existing antibody therapies and discovering novel clinical strategies for melanoma.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:27Tumor Immunotherapy